Menu

“Father of Modern Hematology” Dies

Australian researcher Donald Metcalf, whose discoveries transformed cancer treatment, has passed away at age 85.

Dec 17, 2014
Molly Sharlach

WEHIDonald Metcalf, whose studies of blood cell formation led to improved outcomes for cancer patients, died this week (December 15) at the age of 85. He was diagnosed with metastatic pancreatic cancer in August.

Metcalf earned a medical degree at the University of Sydney in 1953, and spent 60 years as an investigator at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, where he characterized colony stimulating factors (CSFs), which regulate the production of white blood cells. His work on CSFs led to the widespread clinical use of these growth factors to restore immune function in cancer patients undergoing chemotherapy. 

“CSFs are now standard treatment and every year the number of people alive because of Don’s work grows,” wrote WEHI Director Douglas Hilton in a tribute to Metcalf. “There can be no greater legacy for a medical researcher.”

“When he was diagnosed with cancer in August . . . the two things he wanted to do was spend as much time as possible with his wife, Jo, and his daughters, but also to continue to do his research,” Hilton told the Australia’s ABC. “His solution was to have his microscope, which was his valued possession at work, shipped home and it sat on his dining room table . . . he’d be able to sneak in some experiments in the afternoon and then spend the time with his wife, so really that kept going until about a month ago.”

Metcalf’s research has also impacted the fields of blood stem cell transplantation and rheumatoid arthritis treatment. He received several awards during his career, including the Albert Lasker Clinical Medical Research Award in 1993.

He is survived by his wife, four daughters, and six grandchildren.

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT’s new CRISPR Cas12a (Cpf1) Ultra enzyme can target new sites within the genome and with greater efficiency
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen GmbH is excited to announce the release of the NanoPhotometer® N120, an absorbance based UV/VIS Multi Channel Spectrophotometer.
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
To continue to provide new products and services to further advance medical research around the world, today, StemExpress announced the release of their Frozen Leukopak®.